Filter
98
Text search:
remdesivir
Featured
31
5
Language
Document type
55
14
10
7
4
3
2
1
1
1
Countries / Regions
10
8
8
6
6
4
4
4
4
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
53
2
1
1
1
1
Toolboxes
79
10
5
1
1
The World Health Organization (WHO) recognizes the challenges countries face for maintaining their COVID-19 response while addressing competing public health challenges, conflicts, climate change and economic crises. WHO continues to support countries in adjusting COVID-19 strategies to reflect succ
...
The African region reports the highest number of health emergencies of all the WHO regions every year: an average of
2-3 new events every week
The second edition of the joint WHO, WIPO and WTO
publication “Promoting Access to Medical Technologies
and Innovation: Intersections between public health,
intellectual property and trade” (the Trilateral Study),*
published in 2020, included a special insert mappi
...
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan
...
Report of the 23rd WHO Expert Committee on the selection and use of essential medicines
This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)
...
Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease
recommended
To save the lives of mothers and their babies, mitigate complications, and limit the spread of disease, it is critical that recommendations are made on the prevention, treatment, and surveillance of women who are exposed to EVD, acquire EVD during pregnancy or breastfeeding, or survive EVD with ongo
...
Stand 28.9.2020
16-24 February 2020
La Agencia Española de Medicamentos y Producto Sanitarios (AEMPS) está monitorizando de manera continua con los expertos de las agencias europeas, la EMA y el resto de agencias mundiales todos los datos relativos al uso de medicamentos para tratar la COVID-19. Se trata de
...
El presente documento técnico tiene la finalidad de guiar el manejode cuidados intensivosde los pacientes conCOVID-19 con undoble objetivo: lograr el mejor tratamiento del paciente que contribuya a subuena evolución clínica; ygarantizar los niveles adecuados de prevención y control de la
...
(7th Version)
20, March 2020
Le HCSP a fondé ses recommandations sur les connaissances actuellement disponibles en particulier les publications scientifiques relatives au COVID-19 mais aussi de recommandations relatives à la prise en charge des pneumonies post grippales, et des pneumonies sévères en réanimation.
Cet avi
...
COVID Reference 2020.3 DEU
recommended
Tercera versión, 1 de febrero del 2022. Estas orientaciones tienen por objetivo contribuir a que los sistemas de salud prioricen los medicamentos esenciales que deben estar disponibles y ser asequibles para manejar los pacientes en las unidades de cuidado intensivos durante las emergencias de salud
...
Updated July 3, 2020
Updated 10 August 2020
This document presents an essential medicines list (EML) to manage patients in intensive care units (ICUs) with suspected or confirmed COVID-19 diagnosis, which includes active ingredients with dosage form and concentration, and are preferably in the WHO Model Lists of Essent
...
There is no secret to our procedure: the daily scanning of the literature helps us to stay afloat in the never-ending waves of new publications about SARS-CoV-2 and COVID-19. Many papers discussed in the Top 10 will eventually make it into subsequent editions of COVID Reference.
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients
...
Orientação provisória. 2 de setembro de 2020
Questão clínica: Qual é o papel dos corticosteroides sistêmicos no tratamento de pacientes com COVID-19? Público-alvo: O público-alvo consiste principalmente de médicos, seguido por tomadores de decisão na área de saúde.
